ArticleWiener klinische Wochenschrift2021
Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19.
Article in Wiener klinische Wochenschrift, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Article
- Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19.Future science OA · 2024Article
- Article
- The effect of oseltamivir use in critically ill patients with COVID-19: A multicenter propensity score-matched study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- A MOF/DNA luminescent sensing platform for detection of potential COVID-19 biomarkers and drugs.Chemical science · 2023Article
- Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.Frontiers in immunology · 2023Review
- Article
- A predictive model to estimate fever after receipt of the second dose of Pfizer-BioNTech coronavirus disease 2019 vaccine: An observational cohort study.Health science reports · 2022Article
- Efficacy of oseltamivir in the treatment of patients infected with Covid-19.Annals of medicine and surgery (2012) · 2022Article
- A computational study of potential therapeutics for COVID-19 invoking conceptual density functional theory.Structural chemistry · 2022Article
- Impact of COVID-19 on Outpatient Antimicrobial Prescribing Patterns in New York City.Infectious diseases in clinical practice (Baltimore, Md.) · 2021Article
- Targeting Some Enzymes with Repurposing Approved Pharmaceutical Drugs for Expeditious Antiviral Approaches Against Newer Strains of COVID-19.AAPS PharmSciTech · 2021Review
- Review of pharmacologic and immunologic agents in the management of COVID-19.Biosafety and health · 2021Review
- An Examination of COVID-19 Medications' Effectiveness in Managing and Treating COVID-19 Patients: A Comparative Review.Healthcare (Basel, Switzerland) · 2021Review
- Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review.Nutrients · 2021Review
- COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?Infectious disease reports · 2021Review
- Review
- Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2's pathogenicity factors.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince December 2019 coronavirus disease 2019 (COVID-19) outbreaks have occurred in China and many countries around the world. The effectiveness of oseltamivir on COVID-19 suspected outpatients without hypoxia was evaluated.
methodsA total of 16 COVID-19 suspected medical personnel and their cohabitation families without hypoxia, who came to the adult fever clinic from March to June 2020 were studied. All patients received antiviral therapy (oseltamivir) and antibacterial therapy together.
resultsMost of the infected patients were female (10, 63%), 1 had diabetes (6%) and 3 hypertension (19%). The median age was 45 years (interquartile range [IQR] 31-60 years). Oseltamivir administration made the temperature fall within 24 h in part (10, 63%). Clinical data were compared between patients receiving early treatment (ET) with oseltamivir, initiated within 24 h, and patients administered late treatment (LT), initiated after this time point. Duration of fever was shorter in the ET group than in the LT group (31 ± 21 h versus 94 ± 38 h; p < 0.001). The time from fever onset to treatment initiation correlated with duration of fever (r = 0.77; p < 0.001) and the time from peak to decline (r = 0.58; p < 0.05).
conclusionThese findings suggest that early oseltamivir administration may lower the duration of fever in COVID-19 suspected outpatients without hypoxia when it is used in combination with antibacterial therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.